Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Bending, Not Breaking

Philip Seo, MD, MHS  |  Issue: August 2019  |  August 16, 2019

a_v_d / shutterstock.com

a_v_d / shutterstock.com

“And of course, I am not telling you to do it. That would be illegal.”

As a general rule, I try not to instruct my patients to break the law. My business model depends on repeat customers, so placing a patient at risk of getting arrested—even if that risk is remote—doesn’t seem like a good idea. On the other hand, I am a realist. I know my patients will be cracking crabs this summer, even though I have warned them it may make their gout flare. I also know my patients on metho­trexate will sneak a beer now and again, because what’s the point of eating crab if you can’t wash it down with a beer?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

When I take a patient’s interval history, I always tell them I want them to tell me the truth. I don’t want to hear a lightly fictionalized account of some ideal patient whom I have not met. I want them to confess their sins, their failings, their shortcomings, so I can help them get where they need to go. And, if they are planning to do something illegal, anyway, I would like to know that, too.

I am, of course, talking about purchasing drugs from Canada.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Of course, you don’t do this yourself. You do, however, know someone who does. In fact, in 2016, 19 million Americans imported drugs into the U.S. for their personal use.1 Americans have a long tradition of purchasing drugs from Canada, dating to the pre-internet era, when this involved driving the family station wagon to Toronto or Montreal. The internet has added jet fuel to this phenomenon, allowing even the least adventurous patient to price drugs across the border.

The reason you (likely) don’t know anyone who has been arrested for purchasing drugs from Canada is that the government looks the other way. Like marijuana in many states, bringing drugs into the U.S. is illegal, but has been de facto decriminalized. As long as the drugs are imported for personal use and don’t exceed a 90-day supply, the federal government will not prosecute anyone’s grandmother for trying to get a cheaper inhaler.2

But the phenomenon is even bigger than that. One company—CanaRx—has worked for years with 500 American towns, cities and school districts, to facilitate the importation of lower cost, brand-name drugs, for the use of their employees.3

Now states want to get in on the action. In June 2019, Florida Governor Ron DeSantis signed legislation that created two programs designed to facilitate the import of drugs from Canada:

Page: 1 2 3 4 | Single Page
Share: 

Filed under:EthicsOpinionRheuminationsSpeak Out Rheum Tagged with:Canadian drugsdrug costs

Related Articles

    A Comparison of the Canadian and U.S. Healthcare Systems

    February 3, 2012

    The joys and the hazards of the Canadian single-payer universal healthcare program Canadian and the high-capacity and costly U.S. healthcare system.

    Value-Based Purchasing: The Future of US HealthCare?

    August 1, 2009

    Purchasers of healthcare are beginning to take a more active role in ensuring they receive value for their health care dollars, and these savvy shoppers want to develop programs to increase the quality and efficiency of the care they purchase. This movement has given rise to the concept of value-driven healthcare, commonly called value-based purchasing. Over the next three months, “From the College” will take a look at this type of purchasing and provide rheumatologists and rheumatology health professionals with practical advice on how to stand out to these value-based purchasers.

    garagestock/shutterstock.com

    E-Health, Telemedicine Pose Challenges, Offer Benefits for Patients with Arthritis

    August 11, 2016

    A 52-year-old woman comes to the office complaining of a two-month history of pain and swelling in the small joints of her hands, feet and knees. She says, “Doctor, I’ve been searching the Internet, and I think I have rheumatoid arthritis. I have some questions for you.” The healthcare system in the U.S. is changing…

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences